Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).

"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."